Customer Demand Communication and Project Design
Consultation defines objectives; we design a tailored experimental plan.
We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.
At Creative Biolabs, we specialize in providing cutting-edge chimeric RNA-DNA molecule based anti-monkeypox drug discovery solutions. Our expertise and robust platforms empower clients to accelerate their research, offering tailored services and high-quality monkeypox research products to meet diverse scientific needs.
Monkeypox is a zoonotic disease caused by the Monkeypox virus (MPXV), a member of the Orthopoxvirus genus, which also includes variola virus. This double-stranded DNA virus causes a disease characterized by fever, headache, muscle aches, swollen lymph nodes, and a distinctive rash that can lead to severe scarring. While historically endemic in Central and West Africa, global outbreaks have highlighted its potential for wider transmission and the critical need for effective therapeutic interventions.
Chimeric RNA-DNA molecules represent a revolutionary class of nucleic acid therapeutics, ingeniously combining the distinct chemical and functional attributes of both RNA and DNA within a single engineered strand. This hybrid architecture offers significant advantages, including enhanced stability against nuclease degradation, versatile targeting capabilities against various viral and cellular pathways, and the potential for high specificity and potency. Their tunable properties allow for precise optimization of binding affinity and biological activity.
Fig.1 The typical chimeraplast and chimeraplast action.1
Creative Biolabs provides a comprehensive suite of services designed to accelerate the discovery and development of novel anti-Monkeypox drugs utilizing chimeric RNA-DNA molecules. Our integrated platform spans from initial design to in vivo validation, ensuring robust and reliable results for our partners.
We meticulously design and synthesize custom chimeric RNA-DNA molecules, including specialized deoxyribozymes and hammerhead ribozymes, optimized for specific MPXV targets. Our designs incorporate advanced features like double-hairpin capped ends to maximize nuclease resistance and enhance in vitro stability, ensuring the integrity and longevity of the therapeutic molecule.
Our services include rigorous validation of chimeric RNA-DNA molecule binding to specific viral RNA or DNA targets. We employ a range of biophysical and biochemical assays to confirm high-affinity and sequence-specific interactions, which are crucial for effective therapeutic action and minimizing off-target effects.
For chimeric RNA-DNA molecules designed to have catalytic activity, such as ribozymes or deoxyribozymes, we perform comprehensive in vitro cleavage assays. These experiments quantify the chimeric RNA-DNA molecule's ability to cleave target viral nucleic acids, providing critical data on its catalytic efficiency and potency against MPXV.
We conduct advanced cell-based assays to evaluate the antiviral efficacy of chimeric RNA-DNA molecule candidates. This includes assessing the inhibition of MPXV replication in infected cell lines using techniques like quantitative RT-PCR for viral load reduction and immunofluorescence for viral protein expression.
Our in vivo services include comprehensive studies to determine the pharmacokinetic profile and biodistribution of chimeric RNA-DNA molecule candidates in relevant animal models. This provides essential data on absorption, distribution, metabolism, and excretion, informing optimal dosing strategies and delivery methods.
We perform rigorous efficacy studies in established Monkeypox animal models to evaluate the in vivo antiviral activity of lead chimeric RNA-DNA molecule candidates. These studies assess the reduction in viral load, improvement in clinical signs, and overall survival, providing strong evidence of therapeutic potential.
Prioritizing patient safety, we conduct thorough toxicity and safety assessments of chimeric RNA-DNA molecule candidates in preclinical models. These studies identify potential adverse effects and determine the therapeutic window, ensuring that only compounds with favorable safety profiles progress to further development.
Consultation defines objectives; we design a tailored experimental plan.
Finalized design leads to contract signing. Teams and resources are promptly allocated for project launch.
Core lab operations—deoxyribozyme synthesis, in vitro validation, and in vivo studies—executed to high standards.
Data undergoes thorough analysis. Detailed reports compile raw data, results, and conclusions for a complete project overview.
Final results and reports are delivered. We offer follow-up consultations to discuss findings and guide next development steps.
Click the button to contact us for service details and a custom quote.
Chimeric RNA-DNA molecules exert their antiviral effects against Monkeypox through diverse mechanisms, leveraging their hybrid nature. They can be engineered as antisense oligonucleotides, specifically binding to and inhibiting the translation of essential viral messenger RNAs (mRNAs), effectively shutting down viral protein synthesis. Alternatively, chimeric RNA-DNA molecules can function as catalytic molecules, such as ribozymes or deoxyribozymes, precisely cleaving viral RNA or DNA sequences crucial for replication or transcription. This targeted degradation prevents the virus from completing its life cycle, thereby inhibiting its proliferation and spread within host cells.
Precision Chimeric RNA-DNA Molecule Engineering
We utilize advanced bioinformatics and nucleic acid chemistry to design and synthesize highly specific and stable chimeric RNA-DNA molecules, including specialized deoxyribozymes, ensuring optimal targeting of MPXV.
Integrated Discovery Workflow
Our platform offers a seamless, end-to-end solution from initial chimeric RNA-DNA molecule design and synthesis through rigorous in vitro and in vivo validation, streamlining your drug discovery process.
World-Class Expertise
Benefit from the profound knowledge and extensive experience of our team of expert biologists and nucleic acid chemists, ensuring the highest scientific rigor and innovative problem-solving.
Rapid Project Turnaround
Our optimized workflows and state-of-the-art facilities enable efficient project execution and timely delivery of results, accelerating your progress towards lead candidate identification.
Chimeric RNA-DNA molecules are unique hybrid nucleic acids, combining segments of both RNA and DNA within a single strand. This distinct composition provides them with superior characteristics compared to pure RNA or DNA. For instance, the DNA component often confers enhanced stability against enzymatic degradation, while the RNA portion can facilitate specific binding or catalytic functions, leading to improved in vivo performance and versatile targeting capabilities.
We employ sophisticated design algorithms and incorporate specific structural modifications, such as double-hairpin capped ends, to significantly enhance chimeric RNA-DNA molecule stability against nucleases. For specificity, our design process leverages extensive bioinformatics analysis of the MPXV genome to identify highly conserved and unique target sequences, minimizing potential off-target effects and ensuring precise viral inhibition.
Our platform is highly versatile, allowing us to design chimeric RNA-DNA molecules that primarily target viral nucleic acids (mRNA or DNA) for gene silencing or enzymatic cleavage. However, we also explore chimeric RNA-DNA molecule designs that can act as aptamers, binding to specific viral proteins or host factors involved in the viral life cycle, thereby inhibiting their function or disrupting critical protein-protein interactions.
Chimeric RNA-DNA molecule-based therapeutics fall under the broader category of nucleic acid drugs, which have specific regulatory pathways. While we primarily focus on preclinical discovery and development, our team can provide expert consultation and guidance regarding the regulatory landscape. We assist clients by ensuring our preclinical data packages are robust and meet the quality standards often required for subsequent regulatory submissions.
Yes, Creative Biolabs is committed to long-term partnerships. Following the delivery of your project results, we offer dedicated follow-up consultation and scientific support. This includes discussing the implications of the findings, assisting with data interpretation, and providing strategic advice for the next stages of your drug development pipeline, such as IND-enabling studies or clinical trial planning.
At Creative Biolabs, we provide services related to the development of anti-monkeypox drugs to our clients all over the world for your research, if you are interested in our service, please feel free to contact us for more information.
Reference
We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.